Financials data is unavailable for this security.
View more
Year on year Blueprint Medicines Corp grew revenues 22.22% from 204.04m to 249.38m while net income improved from a loss of 557.52m to a smaller loss of 506.98m.
Gross margin | 97.01% |
---|---|
Net profit margin | -29.48% |
Operating margin | -23.54% |
Return on assets | -11.11% |
---|---|
Return on equity | -49.65% |
Return on investment | -13.84% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Blueprint Medicines Corp fell by 43.38m. However, Cash Flow from Investing totalled 274.04m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 436.85m for operations while cash generated from financing totalled 119.23m.
Cash flow per share | -1.82 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.93 |
---|---|
Tangible book value per share | 4.93 |
More ▼
Balance sheet in USDView more
Current ratio | 3.32 |
---|---|
Quick ratio | 3.27 |
Total debt/total equity | 1.23 |
---|---|
Total debt/total capital | 0.5525 |
More ▼